| Spotlight on anti-CD25: daclizumab in MS. | |
| | |
MedLine Citation:
|
PMID: 18808743 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Monoclonal antibodies are a promising new class of therapeutic agents that can be employed to target specific molecules of the immune system or any tissue. They are currently being tested in a number of clinical trials in autoimmune diseases such as multiple sclerosis (MS). One of these, the humanized monoclonal anti-CD25 antibody daclizumab (Zenapax), is directed against the interleukin-2 (IL-2) receptor alpha chain (CD25) that is involved in clonal expansion of autoreactive T-cells by binding of its ligand IL- 2. Several years ago daclizumab was approved for the prevention of renal allograft rejection. Following promising observations in uveitis, daclizumab has since been tested in a number of small clinical trials in MS based on the rationale that blocking CD25 would prevent the expansion of autoreactive T-lymphocytes. Safety and efficacy data from the preliminary clinical exploration as well as findings about the mechanism of action of anti-CD25 treatment are reviewed here. |
| | |
Authors:
|
Dr Sven Schippling; Roland Martin |
Related Documents
:
|
8222913 - Immunodiagnosis of schistosoma japonicum infection in china. 15709893 - Immune function testing of human pharmaceuticals: regulatory overshoot? 15618173 - Optimization of salmonella enterica serovar typhi deltaaroc deltassav derivatives as ve... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: International MS journal / MS Forum Volume: 15 ISSN: 1352-8963 ISO Abbreviation: Int MS J Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2008-09-23 Completed Date: 2008-11-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9804403 Medline TA: Int MS J Country: England |
Other Details:
|
Languages: eng Pagination: 94-8 Citation Subset: IM |
Affiliation:
|
Neurologische Klinik und Poliklinik, Universitatsklinikum Hamburg Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. s.schippling@uke.uni-hamburg.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
adverse effects,
therapeutic use* Clinical Trials as Topic Humans Immunoglobulin G / adverse effects, therapeutic use* Immunosuppressive Agents / adverse effects, therapeutic use* Interleukin-2 Receptor alpha Subunit / antagonists & inhibitors* Multiple Sclerosis, Chronic Progressive / drug therapy* Multiple Sclerosis, Relapsing-Remitting / drug therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Immunoglobulin G; 0/Immunosuppressive Agents; 0/Interleukin-2 Receptor alpha Subunit; 152923-56-3/daclizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Wilhelm Uhthoff: a phenomenon 1853 to 1927.
Next Document: Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays.